Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 8, 2025

E-Cadherin (4A2)

RRID:AB_2728770 Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 14472, RRID:AB_2728770)

Antibody Information

URL: http://antibodyregistry.org/AB_2728770

Proper Citation: (Cell Signaling Technology Cat# 14472, RRID:AB_2728770)

Target Antigen: E-Cadherin

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F

Antibody Name: E-Cadherin (4A2)

Description: This monoclonal targets E-Cadherin

Target Organism: rat, mouse, human

Antibody ID: AB_2728770

Vendor: Cell Signaling Technology

Catalog Number: 14472

Record Creation Time: 20231110T033636+0000

Record Last Update: 20240725T100142+0000

Ratings and Alerts

No rating or validation information has been found for E-Cadherin (4A2).

No alerts have been found for E-Cadherin (4A2).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Kim B, et al. (2024) CRACD loss induces neuroendocrine cell plasticity of lung adenocarcinoma. Cell reports, 43(6), 114286.

Gupta T, et al. (2024) Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis. Cancer cell, 42(5), 797.

Liu H, et al. (2024) Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma. Cancer cell, 42(6), 1067.

Wang X, et al. (2024) Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer cell, 42(10), 1729.

Labrosse KB, et al. (2024) Protocol for quantifying drug sensitivity in 3D patient-derived ovarian cancer models. STAR protocols, 5(3), 103274.

Huang P, et al. (2024) Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. Cell host & microbe, 32(8), 1365.

Yu L, et al. (2024) FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology. Cell metabolism.

Olotu O, et al. (2024) Germline-specific RNA helicase DDX4 forms cytoplasmic granules in cancer cells and promotes tumor growth. Cell reports, 43(7), 114430.

He B, et al. (2024) Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling. Cell reports. Medicine, 5(5), 101510.

O'Guinn ML, et al. (2024) FXR deletion attenuates intestinal barrier dysfunction in murine acute intestinal inflammation. American journal of physiology. Gastrointestinal and liver physiology, 327(2), G175.

Li Q, et al. (2023) AID-induced CXCL12 upregulation enhances castration-resistant prostate cancer cell metastasis by stabilizing ?-catenin expression. iScience, 26(12), 108523.

Thongnak L, et al. (2023) Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPAR? pathway. Archives of pharmacal research, 46(5), 408.

Li Q, et al. (2023) Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice. Cancer cell, 41(8), 1450.

Bera S, et al. (2023) Regulation of SELENOF translation by eIF4a3: Possible role in prostate cancer progression. Molecular carcinogenesis, 62(12), 1803.

Yang W, et al. (2023) SHOX2 promotes prostate cancer proliferation and metastasis through disruption of the Hippo-YAP pathway. iScience, 26(9), 107617.

Pohlers M, et al. (2023) Th17 cells target the metabolic miR-142-5p-succinate dehydrogenase subunit C/D (SDHC/SDHD) axis, promoting invasiveness and progression of cervical cancers. Molecular oncology.

Ma Y, et al. (2023) Cytosolic LPS-induced caspase-11 oligomerization and activation is regulated by extended synaptotagmin 1. Cell reports, 42(7), 112726.

Basile G, et al. (2023) Excess pancreatic elastase alters acinar-? cell communication by impairing the mechano-signaling and the PAR2 pathways. Cell metabolism, 35(7), 1242.

Jovanovi? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell reports, 42(12), 113564.

Kombiyil S, et al. (2023) In Vitro Anti-cancer Effect of Crataegus oxyacantha Berry Extract on Hormone Receptor Positive and Triple Negative Breast Cancers via Regulation of Canonical Wnt Signaling Pathway. Applied biochemistry and biotechnology, 195(4), 2687.